Endocrine and Metabolic Disease Unit, Department of Medicine, ASST Spedali Civili of Brescia, Brescia, Italy.
Molecular Medicine Laboratory, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Mol Genet Genomic Med. 2023 Apr;11(4):e2126. doi: 10.1002/mgg3.2126. Epub 2023 Feb 2.
To perform genetic screening for ARMC5 gene germline pathogenic variants in patients with primary bilateral macronodular adrenal hyperplasia (PBMAH).
In a group of 10 PBMAH patients, we performed complete sequencing of the coding region of the ARMC5 gene and MLPA analysis for large deletion detection. In subjects with the ARMC5 variant, we searched ARMC5 gene somatic variants on tumor samples.
Among 10 PBMAH patients, we identified four ARMC5 germline variants (40%). One variant, c:174dupC p.Glu59Argfs*44, was already known; one variant p.Gly323Asp, was already reported and classified as likely disease-causing VUS (class 3-4); two variants p.Leu596Arg and p.Arg811Pro, were never reported before. For p.Gly323Asp and p.Arg811Pro, we identified second deleterious variants at the somatic level, enforcing the possible pathogenic effect of germline variants.
Our results underscore the importance of performing genetic testing also in sporadic PBMAH patients and broaden the spectrum of molecular variants involved in PBMAH syndrome.
对原发性双侧结节性肾上腺增生症(PBMAH)患者的 ARMC5 基因种系致病性变异进行基因筛查。
在一组 10 名 PBMAH 患者中,我们对 ARMC5 基因的编码区进行了完整测序,并进行了 MLPA 分析以检测大片段缺失。在存在 ARMC5 变异的受试者中,我们在肿瘤样本中搜索 ARMC5 基因体细胞变异。
在 10 名 PBMAH 患者中,我们发现了四个 ARMC5 种系变异(40%)。一个变异 c:174dupC p.Glu59Argfs*44 是已知的;一个变异 p.Gly323Asp 已经报道并归类为可能致病的 VUS(3-4 级);另外两个变异 p.Leu596Arg 和 p.Arg811Pro 以前从未报道过。对于 p.Gly323Asp 和 p.Arg811Pro,我们在体细胞水平上发现了第二个有害变异,这增强了种系变异的可能致病效应。
我们的结果强调了对散发性 PBMAH 患者进行基因检测的重要性,并拓宽了参与 PBMAH 综合征的分子变异谱。